Clinical trials: Staph Aureus Infection
Methicillin-Resistant Staphylococcus Aureus, Atopic Dermatitis
The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)
Staphylococcus aureus (S.aureus) is a bacterium that causes many painful skin and soft tissue conditions, such as scalded-skin syndrome, boils, or impetigo.
- Conditions
- Methicillin-Resistant Staphylococcus Aureus, Atopic Dermatitis, Eczema Herpeticum, MRSA
- Trial name
- MRSA (NCT00822276)
- Where
- 2 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
STAPHYLOCOCCAL INFECTIONS
Study of the Colonic Carriage of Staphylococcus Aureus in a Prospective Cohort of Patients Undergoing Endoscopic Screening for Digestive Cancer in the University Hospital of Saint-Etienne
Epidemiological study aiming to describe the carriage (nasal, throat, groin, rectal and colonic) of S. aureus in patients without chronic digestive disease who are going to have a colonoscopy for cancer screening.
- Trial name
- ColoStaph (NCT02502474)
- Testing
- Staphylococcus aureus carriage
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Staphylococcus Aureus
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects
This is a Phase 1, first time in human study enrolling approximately 33 healthy adult subjects (18-65 yrs) from one study site. The purpose of this study is to evaluate the safety, tolerability and PK of MEDI4893 in healthy adult…
- Trial name
- NCT01769417
- Testing
- MEDI4893
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Bacteria Infection Mechanism
Study of the Nasal Intracellular Reservoir of Staphylococcus Aureus in Patients With S. Aureus Bacteremia
Staphylococcus aureus bacteremia is a serious infection associated with a high mortality rate (with or without associated infective endocarditis (IE)), long hospital stays and multiple complications, due to the terrain in which…
- Trial name
- RISTA (NCT06594250)
- Testing
- Nasal swab, Venous sampling, Antibiotic treatment
- Where
- France
- Volunteers
- 405 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Hyper-Immunoglobulin E. Syndrome (HEIS), Chronic Granulomatous Disease (CGD)
Skin Immunity Sample Collection Involving Blisters and Biopsies
Background: The way the body heals and protects itself from getting sick is called the immune response. Some people with weak immune systems get sick often or get rashes and skin infections.
- Trial name
- NCT03921515
- Testing
- Blister induction, Skin Biopsies
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Staphylococcal Infection
Staphylokinase and ABO Group Phenotype: New Players in Staphylococcus Aureus Implant-associated Infections Development
The purpose of this study is to identify bacterial and/or clinical features involved in the pathogenesis of Staphylococcus aureus implant-associated infections (IAI). Materials \& methods: In total, 57 IAI S.
- Trial name
- NCT02812446
- Testing
- IAI infection, Staphylococcus aureus nasal carriage infection
- Where
- France
- Volunteers
- 88 people
- Sponsor
- Nantes University Hospital
Staphylococcus Aureus Bacterial Contamination
Investigation of Antibacterial Effect of Levobupivacaine on Staphylococcus Aureus
This experimental in vitro study aimed to investigate the antibacterial effect of levobupivacaine on Staphylococcus aureus in a patient-controlled analgesia (PCA) model at concentrations commonly used for postoperative pain…
- Trial name
- NCT07285759
- Testing
- Levobupivacaine, Fentanyl, Saline
- Volunteers
- 40 people
- Sponsor
- Dokuz Eylul University
Staphylococcus Aureus Infection
Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
Study to determine the efficacy, safety and tolerability of two concentrations of XF-73 nasal gel in combination with body and face washing with chlorhexidine gluconate cloths in eradicating nasal carriage of Staphylococcus…
- Trial name
- NCT02282605
- Testing
- XF-73 nasal gel, Chlorhexidine gluconate 2% topical cloths
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Destiny Pharma Plc
Staphylococcus (S.) Aureus Infection
Staphylococcus Aureus Caught in Action at the Site of Infection
This study is to obtain a comprehensive view of S. aureus adaptations in the infected human host and (i) to improve the understanding of the interface between antibiotic therapy, resistance development and virulence factor…
- Trial name
- PROSA (NCT04781569)
- Testing
- data collection, blood draw, nose swabs
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Skin and Soft Tissue Infections (SSTIs)
S. Aureus, Skin and Soft Tissue Infections
Methicillin-resistant Staphylococcus aureus (MRSA) is reported as one of the main causative pathogen of community acquired SSTIs.
- Trial name
- SSTIs (NCT02796742)
- Testing
- Collecting samples from all patients presenting with SSTIs requiring drainage
- Where
- France
- Volunteers
- 249 people
- Sponsor
- Hospices Civils de Lyon
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
The purpose of this superiority study is to evaluate the efficacy and safety of exebacase in addition to standard of care antibiotics (SoCA) compared with SoCA alone for the treatment of patients with Staphylococcus aureus (S.
- Trial name
- DISRUPT (NCT04160468)
- Testing
- Exebacase
- Where
- 55 sites in United States
- Volunteers
- 259 people
- Sponsor
- ContraFect
Staphylococcus Aureus Infection, Bone and Joint Infection
Recurrent S. Aureus Infections in Osteoarticular Infections
Staphylococcus aureus osteoarticular infections, in particular those associated with the presence of implant, relapse in 20% of cases.
- Trial name
- RELAPSTAPH (NCT04712123)
- Testing
- relapse due to S. aureus
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Hospices Civils de Lyon
Staphylococcus Aureus Bacteremia
Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia
The primary objective is to determine if early infectious disease (ID) consultation (defined as within 48 hours of a positive blood culture) will reduce mortality rates from Staphylococcus aureus bacteremia (SAB).
- Trial name
- NCT00622882
- Testing
- infectious disease specialist consultation
- Where
- Singapore
- Volunteers
- 200 people
- Sponsor
- National University Hospital, Singapore
Bacterial Pneumonia
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
Study 0019 (NCT00124020) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
- Trial name
- ATTAIN2 (NCT00124020)
- Testing
- Telavancin, Vancomycin
- Where
- Israel
- Volunteers
- 771 people
- Sponsor
- Cumberland Pharmaceuticals
Staphylococcal Infections, Joint Prosthesis
StaphVAX Immunogenicity in Orthopedic Implant Patients
S. aureus is the most common pathogen involved in prosthetic joint infection. StaphVAX® is a vaccine to prevent these infections, which conjugates the purified capsular polysaccharides of S. aureus to a carrier protein.
- Trial name
- NCT00211926
- Testing
- S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Nabi Biopharmaceuticals
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
Having bacteria in the blood can be very dangerous. This is called bacteraemia (or bacteremia) or bloodstream infection. It can lead to problems across the whole body, which is what happens in sepsis.
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia, Sepsis Bacterial, Bloodstream Infection
- Trial name
- PET-SAB (NCT05361135)
- Testing
- PET/CT
- Volunteers
- 820 people
- Sponsor
- University College, London
Staphylococcus Aureus Pneumonia, Lung Diseases
Mucoid Staphylococcus Aureus in Cystic Fibrosis Airways
Recently, the investigators described a new mucoid phenotype of Staphylococcus aureus cultured from the airways of cystic fibrosis (CF) patients.In this observational study, the investigators plan to determine the prevalence of…
- Conditions
- Staphylococcus Aureus Pneumonia, Lung Diseases, Cystic Fibrosis, Lung Function Decreased
- Trial name
- mucostaph (NCT04171583)
- Where
- 13 sites in Austria, Germany
- Volunteers
- 628 people
- Sponsor
- University Hospital Muenster
Staphylococcus Aureus
Penicillin Against Flucloxacillin Treatment Evaluation
There is theroretical superiority with benzylpenicillin over orther anti-staphylococcal penicillins (ASP) for treatment of penicillin susceptible S.
- Trial name
- PANFLUTE (NCT03632642)
- Testing
- Benzylpenicillin, Flucloxacillin
- Where
- Australia
- Sponsor
- The University of Queensland
MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients
Vancomycin is an essential antimicrobial which is frequently used in the ICU for suspected methicillin-resistant Staphylococcus aureus (MRSA) infection.
- Trial name
- CIV (NCT01786161)
- Testing
- Vancomycin continuous infusion, Vancomycin intermittent dosing interval
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Massachusetts General Hospital
Staphylococcus Aureus
Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial
This study involves the use of investigational vaccines. A vaccine is a medicine that causes the body to make antibodies. Antibodies help destroy foreign substances that enter the body.
- Trial name
- NCT01011335
- Testing
- Monovalent rAT, Monovalent rLukS-PV, Bivalent rLukS-PV / rAT
- Where
- 2 sites in United States
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine